SCHEMBL15764258

SCHEMBL15764258

CCOC(=O)C1CCCc2c1c1c(OC)ccc(Cl)c1n2CCOC(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSPO P30536 3/20 0.43
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
STAT6 P42226 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
SCN1A P35498 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
KMT2A Q03164 1/20 0.35
KCNH2 Q12809 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12748249 0.89 TSPO (0.43) TSPOALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL12748246 0.89 TSPO (0.43) TSPOALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL12748227 0.89 TSPO (0.43) TSPOALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL420135 0.89 TSPO (0.41) TSPOALDH1A1MAPTKMT2APKM
SCHEMBL6688729 0.86 TSPO (0.43) TSPOALDH1A1KMT2A
SCHEMBL416930 0.85 TSPO (0.54) TSPO
SCHEMBL12748229 0.80 TSPO (0.44) TSPOALDH1A1TAS1R3TAS1R1
SCHEMBL12748236 0.80 TSPO (0.44) TSPOALDH1A1TAS1R3TAS1R1
SCHEMBL12748241 0.80 TSPO (0.44) TSPOALDH1A1TAS1R3TAS1R1
SCHEMBL416598 0.79 TSPO (0.42) TSPOKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10709798-B2 Crystallization process of tricyclic indole derivatives GE HEALTHCARE LIMITED (GB) 2020-07-14 US disclosed
US-20150335766-A1 CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2015-11-26 US disclosed
US-20150335766-A1 CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2015-11-26 US disclosed
WO-2014083113-A1 CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES GE HEALTHCARE LIMITED (GB) 2014-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335766-A1 CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES IDO1, IDO2, TPH1 TSPO 3643/4885ALDH1A1 3828/4885MAPT 31/4885
US-10709798-B2 Crystallization process of tricyclic indole derivatives IDO1, IDO2, TPH1 TSPO 3643/4885ALDH1A1 3828/4885MAPT 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.